​

Rigel Pharmaceuticals (RIGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RIGL Stock Forecast

Rigel Pharmaceuticals (RIGL) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $1.50, with a high of $2.00 and a low of $1.00. This represents a -93.33% decline from the last price of $22.49.

- $6 $12 $18 $24 $30 High: $2 Avg: $1.5 Low: $1 Last Closed Price: $22.49

RIGL Stock Rating

Rigel Pharmaceuticals stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

RIGL Forecast vs Benchmarks

TypeNameUpside
StockRigel Pharmaceuticals-93.33%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$22.49$22.49$22.49
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25114--6
Dec, 24114--6
Nov, 24124--7
Oct, 24124--7
Sep, 24124--7
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 17, 2022Piper Sandler$2.00$1.5628.21%-91.11%
Jun 08, 2022Eun YangJefferies$1.00$0.7140.85%-95.55%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 11, 2024CitigroupBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Aug 07, 2024H.C. WainwrightBuyBuyhold
Dec 02, 2022CitigroupBuyupgrade
Aug 18, 2022H.C. WainwrightBuyBuyhold
Aug 16, 2022Piper SandlerNeutralNeutralhold
Jun 09, 2022BMO CapitalOutperformOutperformhold
Jun 08, 2022JefferiesBuydowngrade
Jun 08, 2022H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.18$-0.11$-0.36$-0.14-----
Avg Forecast$-1.72$-1.02$-4.53$-1.70$0.39$1.12$1.87$1.14$1.12
High Forecast$-1.87$-1.11$-4.67$-1.88$0.16$0.56$0.93$0.17$1.10
Low Forecast$-1.56$-0.92$-4.30$-1.34$0.58$1.56$3.21$1.82$1.13
Surprise %-89.53%-89.22%-92.05%-91.76%-----

Revenue Forecast

$50M $100M $150M $200M $250M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$108.62M$149.24M$120.24M$116.88M-----
Avg Forecast$108.56M$150.63M$97.78M$114.73M$171.80M$198.85M$228.12M$244.06M$266.78M
High Forecast$100.46M$139.39M$93.90M$113.31M$169.67M$194.49M$228.11M$241.38M$263.48M
Low Forecast$115.81M$160.69M$100.02M$115.84M$173.46M$202.15M$228.12M$246.74M$269.37M
Surprise %0.06%-0.92%22.97%1.88%-----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.39M$-17.91M$-61.60M$-25.09M-----
Avg Forecast$-300.00M$-177.99M$-79.04M$-25.09M$3.88M$23.53M$36.95M$17.30M$19.40M
High Forecast$-326.07M$-193.45M$-94.84M$-30.11M$2.77M$9.83M$16.22M$2.91M$19.09M
Low Forecast$-270.90M$-160.72M$-63.23M$-20.07M$10.16M$27.07M$55.86M$31.69M$19.65M
Surprise %-89.87%-89.94%-22.07%------

RIGL Forecast FAQ

Is Rigel Pharmaceuticals stock a buy?

Rigel Pharmaceuticals stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rigel Pharmaceuticals is a favorable investment for most analysts.

What is Rigel Pharmaceuticals's price target?

Rigel Pharmaceuticals's price target, set by 5 Wall Street analysts, averages $1.5 over the next 12 months. The price target range spans from $1 at the low end to $2 at the high end, suggesting a potential -93.33% change from the previous close price of $22.49.

How does Rigel Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Rigel Pharmaceuticals stock forecast shows a -93.33% downside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Rigel Pharmaceuticals over the past three months?

  • January 2025: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 16.67% Strong Buy, 16.67% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 14.29% Strong Buy, 28.57% Buy, 57.14% Hold, 0% Sell, 0% Strong Sell.

What is Rigel Pharmaceuticals’s EPS forecast?

Rigel Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is 0.39 for 2024, a -378.57% decrease from the reported $-0.14 in 2023. The prediction for 2025 is $1.12, $1.87 for 2026, $1.14 for 2027, and $1.12 for 2028.

What is Rigel Pharmaceuticals’s revenue forecast?

Rigel Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $171.8M for 2024, a 46.98% increase from the reported $116.88M in 2023. The forecast for 2025 is $198.85M, $228.12M for 2026, $244.06M for 2027, and $266.78M for 2028.

What is Rigel Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Rigel Pharmaceuticals's average annual net income forecast is $3.88M for 2024, reflecting a -115.47% decrease from the reported $-25.091M in 2023. The projection for 2025 is $23.53M, $36.95M for 2026, $17.3M for 2027, and $19.4M for 2028.